Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group studyShaji Kumar, J Feather, Antje Hoering et al.|Leukemia|2011Cited by 721
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disordersJens Hillengaß, Suzanne Lentzsch, Saad Z. Usmani et al.|The Lancet Oncology|2019Cited by 493
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trialPaul G. Richardson, Yen Charles, Albert Oriol et al.|The Lancet Oncology|2019Cited by 383
Immunoelectron microscopy and mass spectrometry for classification of amyloid depositsNiels Abildgaard, Niels Marcussen|Amyloid|2019Cited by 62